Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.

Volume: 16, Issue: 6, Pages: 597 - 611
Published: Jul 7, 2020
Abstract
In the COMPASS trial, the combination of rivaroxaban 2.5 mg twice daily and low-dose aspirin 75-100 mg daily produced a net clinical benefit of 20% in patients with chronic atherosclerotic vascular disease because it reduced major adverse events by 24% and overall mortality by 18% despite an initial increase in major bleeding. In this paper, we examine the rationale for targeting coagulation factor Xa in patients with atherosclerosis, summarize...
Paper Details
Title
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Published Date
Jul 7, 2020
Volume
16
Issue
6
Pages
597 - 611
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.